Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xavier Bosch

Showing results (631-640 of 681) with videos related to

Pageof 69
Sort By:
Cancers|August 12, 2022
Concordance of p16<sup>INK4a</sup> and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International StudyMarisa Mena, Xin Wang, Sara Tous, et al.
Environmental Health : a Global Access Science Source|November 3, 2023
Occupational exposure to pesticides and endometrial cancer in the Screenwide case-control studyArnau Peñalver-Piñol, Yolanda Benavente, Jon Frias-Gomez, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
Virology|July 26, 2005
Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18Jose C Prado, Itzel E Calleja-Macias, Hans-Ulrich Bernard, et al.
American Journal of Preventive Medicine|December 28, 2020
Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European CountriesClaudia Robles, Laia Bruni, Amelia Acera, et al.
Health Policy (Amsterdam, Netherlands)|April 13, 2015
Towards a framework for evaluating and grading evidence in public healthThomas Harder, Muna Abu Sin, Xavier Bosch-Capblanch, et al.
International Journal of Cancer|August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSuzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
Lancet (London, England)|July 3, 2007
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialJorma Paavonen, David Jenkins, F Xavier Bosch, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Pageof 69

Showing results (631-640 of 681) with videos related to

Sort By:
Pageof 69
Cancers|August 12, 2022
Concordance of p16<sup>INK4a</sup> and E6*I mRNA among HPV-DNA-Positive Oropharyngeal, Laryngeal, and Oral Cavity Carcinomas from the ICO International StudyMarisa Mena, Xin Wang, Sara Tous, et al.
Environmental Health : a Global Access Science Source|November 3, 2023
Occupational exposure to pesticides and endometrial cancer in the Screenwide case-control studyArnau Peñalver-Piñol, Yolanda Benavente, Jon Frias-Gomez, et al.
Papillomavirus Research (Amsterdam, Netherlands)|July 20, 2017
Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine - A combined analysis of five phase III clinical trialsLone K Petersen, Jaime Restrepo, Edson D Moreira, et al.
Virology|July 26, 2005
Worldwide genomic diversity of the human papillomaviruses-53, 56, and 66, a group of high-risk HPVs unrelated to HPV-16 and HPV-18Jose C Prado, Itzel E Calleja-Macias, Hans-Ulrich Bernard, et al.
American Journal of Preventive Medicine|December 28, 2020
Determinants of Human Papillomavirus Vaccine Uptake by Adult Women Attending Cervical Cancer Screening in 9 European CountriesClaudia Robles, Laia Bruni, Amelia Acera, et al.
Health Policy (Amsterdam, Netherlands)|April 13, 2015
Towards a framework for evaluating and grading evidence in public healthThomas Harder, Muna Abu Sin, Xavier Bosch-Capblanch, et al.
International Journal of Cancer|August 20, 2016
Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trialSuzanne M Garland, Jorma Paavonen, Unnop Jaisamrarn, et al.
Lancet (London, England)|July 3, 2007
Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trialJorma Paavonen, David Jenkins, F Xavier Bosch, et al.
International Journal of Cancer|October 16, 2010
Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccineKevin A Ault, Elmar A Joura, Susanne K Kjaer, et al.
Papillomavirus Research (Amsterdam, Netherlands)|October 28, 2017
Human papillomavirus detection in cervical neoplasia attributed to 12 high-risk human papillomavirus genotypes by regionXavier Castellsagué, Kevin A Ault, F Xavier Bosch, et al.
Pageof 69